Saturday, February 21, 2026
Denver, Colorado
The Long-Acting Extended Release Antiretroviral Research Resource Program (LEAP) virtually convened clinicians, investigators, developers, community advocacy groups, not-for-profit institutions and regulatory authorities. Attendees shared their diverse perspectives and discussed updates, challenges and future directions in the development of LA formulations. The meeting served as a forum to collectively advance the long-acting field. The Workshop consisted of four Plenary Sessions and four Focus Groups. Below, you’ll find links to video recordings and text summaries of the Plenary and Focus Group presentations.
• View PDF of the full workshop proceedings (TBA)
• View key to abbreviations (TBA)
Carl Dieffenbach, Senior Advisor to the Office of the Director, Fogarty International Center
Welcome
[Opening remarks]
Charles Flexner, Director LEAP, Johns Hopkins University
Overview of Workshop
[Opening remarks]
PLENARY SESSION 1 – Access
Chair: Elaine Abrams, Columbia University
Francois Venter, Ezintsha
Global Access to Long-Acting Formulations for HIV: A Country Perspective
[Presentation]
Sunil Solomon, Johns Hopkins University
Considerations for the Development of Long-Acting Formulations for People Who Use Drugs
[Presentation]
Moherndran Archary, University of Kwazulu-Natal
Availability of LA Products for Children and Adolescents: When?
[Presentation]
Global Access to Long-Acting Formulations for HIV: A Community Perspective –
Access Presentation & Panel Discussion
Imelda Mahaka, Pangea Zimbabwe AIDS Trust
Ronald Ssenyonga, Makerere University
Panel Moderator: Paul Domanico, Clinton Health Access Initiative
[Presentation]
Focus Group 1 Report-Back: Best Practices for Managing HIV/HBV Coinfection in Those Starting or Switching to LA HIV Treatment
Chair: Chloe Thio, JHU
Co-Chair: Jordan Feld, UHN Research
Rapporteur: Monica Gandhi, UCSF
[Presentation]
Panel Discussion
ALL
[Presentation]
PLENARY SESSION 2 – Products
Chair: Paul Domanico, Clinton Health Access Initiative
Roger Ptak, NIH
Preclinical Development of Long-Acting Anti-Infective Drugs and Formulations Supported by NIH
[Presentation]
Chris Vinnard, Gates Medical Research Institute
Long-Acting Injectable Agents as Tools to End TB: An Overview of Activities Supported by the Gates Medical Research Institute
[Presentation]
David Thomas, Johns Hopkins University
LONGEVITY Formulation Development for HCV and TB
[Presentation]
Rodney Ho, University of Washington
All-in-one LA-TLD product for HIV treatment reached IND status
[Presentation]
Huub Gelderblom, HIV Vaccine Trials Network
(Part 1 - Supporting Perspective) Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Excited
[Presentation]
Daniel Kuritzkes, Harvard University
(Part 2 - Counter-Perspective) Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Cautious
[Presentation]
Rebuttals and Discussion
ALL
[Presentation]
PLENARY SESSION 3 – Products
Chair: Kimberly Scarsi, University of Nebraska Medical Center
Lionel Tan, ViiV Healthcare | Alex Rinehart, ViiV Healthcare
Current Status of the ViiV LA/ER Pipeline
[Presentation]
Luisa Stamm, Merck
Current Status of the Merck LA/ER Pipeline
[Presentation]
Moupali Das, Gilead Sciences | Martin Rhee, Gilead Sciences
Current Status of the Gilead LA/ER Pipeline
[Presentation]
Vivian Cox, Johnson & Johnson
Current Status of the J&J Tuberculosis LA/ER Pipeline
[Presentation]
Focus Group 2 Report-Back: Best Practices for Managing HIV/HBV Coinfection in Those Starting or Switching to LA HIV Treatment
Chair: Brian Kearney, Exavir Therapeutics
Co-Chair: Paul Domanico, CHAI
Rapporteur: Keith Crawford, NIH
[Presentation]
Industry Roundtable
ViiV, Merck, Gilead, J&J & Generic Representatives
[Presentation]
PLENARY SESSION 4 – Implementation
Chair: David Thomas, Johns Hopkins University
Focus Group 3 Report-Back: Ending the HIV Epidemic—Is Lenacapavir the Answer?
Chair: Sinead Delany-Moretlwe, Wits RHI
Co-Chair: Angela Colbers, Radboud UMC
Rapporteur: Ethel Weld, JHU
[Presentation]
Geri Donenberg, NIH
What Is Implementation Science, and What Is Its Role in the NIH Research Portfolio?
[Presentation]
Mike Reid, PEPFAR
The New PEPFAR: Implications for LA Treatment and Prevention
[Presentation]
José Bauermeister, University of Pennsylvania
Introduction to the LEAP User Preferences Core
[Presentation]
Focus Group 4 Report-Back: User Preferences Research—Specific Aims and Strategic Plans
Chair: José Bauermeister
Co-Chair: Rachel Bender Ignacio
Rapporteur: Karine Dubé
[Presentation]